Thank you to our ACRO 2026 sponsors!

Want to join this list of sponsors for ACRO 2026: The Radiation Oncology Summit? Email our Industry Relations Manager Lencie Gradishar today!

Corporate Sponsors

Diamond Members:

At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit www.varian.com.   

Platinum Members:

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

 Gold Members:

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer with its innovative therapy, Tumor Treating Fields (TTFields). Currently approved in certain countries for treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma, ongoing and completed clinical trials are exploring treatment with TTFields in new cancer indications. For additional information, please visit Novocure.com and follow @Novocure on LinkedIn.

OncoBeta offers a groundbreaking treatment option for patients with non-melanoma skin cancer (NMSC) – the world’s most prevalent cancer. Rhenium-SCT® utilizes the Beta emitter radioisotope Rhenium-188 to painlessly treat NMSC, without the need for invasive surgery, therefore providing positive aesthetic outcomes. In most cases, treatment with Rhenium-SCT only requires one quick, personalized treatment.
OncoBeta is committed to changing the way people think about NMSC treatment, leading the field in innovation, and improving patients’ quality of life.

Silver Members:

Servier Pharmaceuticals: As the U.S. affiliate of the Servier Group, Servier Pharmaceuticals is focused on delivering transformative oncology and neurology medicines that fill a critical need for patients who are underserved by current therapies. Governed by a non-profit foundation, Servier Group’s private corporate governance enables the company to combine its resources and global network with cutting-edge science and creativity to develop tailored solutions that drive meaningful progress for patients.  For more information, visit Servier.us and follow Servier on LinkedIn.

Bronze Members:

Bayer is committed to delivering science for a better life by advancing a portfolio of innovative oncology treatments. We prioritize patients’ needs by researching and developing medicines that have the potential to enhance cancer treatment. With passion, dedication, and determination, we explore new targets and pathways in multiple forms of cancers. Our oncology franchise includes products and compounds in various stages of clinical development, aiming to make a meaningful impact on patient care.

Beekley Medical's broad range of single-use disposable products for radiation oncology help you save time, improve clinical efficacy, maximize productivity, and create a more positive patient experience in all areas of treatment planning. 

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals.  For more information, please visit www.blueearthdiagnostics.com

Radiation Business Solutions empowers oncologists and hospitals to elevate their oncology programs, delivering impactful solutions that enhance patient care and drive program success.

We look forward to being a part of this prestigious event and contributing to its success.

Exhibitors

 At Brainlab, we digitize medical workflows, from diagnosis to therapy, to offer clinicians and patients better treatment possibilities. Our innovative digital ecosystem forms the basis for modern healthcare technology in 4000 hospitals in 120 countries. At the forefront of health technology for over 35 years, Munich-based Brainlab employs around 2000 people with expertise across the entire healthcare value chain in 25 locations worldwide.

Like and follow Brainlab on LinkedIn, Twitter, Facebook and Instagram.

   

Decipher by Veracyte:  Veracyte offers the Decipher Prostate Genomic Classifier to help with treatment planning for prostate cancer. Decipher Prostate provides prognostic information to help assess each patient’s individual risk and has been validated in over 85 studies as the most accurate predictor of metastasis, prostate cancer-specific mortality, and overall survival.

MIM Software, a GE HealthCare Company, provides practical imaging solutions in the fields of Radiation Oncology, Radiology, Nuclear Medicine, Urology, Neuroimaging, and Cardiac imaging. MIM® offers solutions for computer workstations as well as mobile and cloud-based platforms. MIM products are sold globally to imaging centers, hospitals, specialty clinics, research organizations, and pharmaceutical companies.

Sumitomo Pharma America and Pfizer Oncology are working together to redefine care for millions of patients living with cancer, and aspire to provide medicines that can improve lives and change treatment paradigms. By combining Sumitomo Pharma America’s commitment to purpose-driven science with Pfizer’s deep heritage and leadership in oncology, we are uniquely positioned to provide innovative treatments that fulfill significant unmet needs and make a meaningful difference in people’s lives.